Photo of Paul E. Goss,   FRCP, MB BCh, PhD

Paul E. Goss, FRCP, MB BCh, PhD

Massachusetts General Hospital

Massachusetts General Hospital

Paul E. Goss, FRCP, MB BCh, PhD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Director, Breast Cancer Research, MGH Cancer Center, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Paul Goss is the Research Director of the Breast Program at MGH, Co-Director of the DFHCC and Director Avon Center of Excellence. Dr. Goss' responsibilities include assisting and guiding the internal and National and International clinical and translational breast cancer research studies. He also leads large practice changing clinical trials in early stage breast cancer and in breast cancer prevention. Three areas are currently encompassed within these trials: optimizing endocrine therapy in treatment and prevention; application of anti-Her2 therapies in early stage disease and; studies of bone metabolism in early stage cancer therapies and most recently the role of rank ligand inhibition in the prevention of breast cancer recurrence and prevention of new primary disease. Translational areas of focus include: bone metabolism; tumor signatures; pharmacogenomics of toxicities and outcomes; mammographic density; quality of life; cost effectiveness. Dr. Goss leads a new International Program which focuses on: clinical trials; tissue repositories from clinical trials, intended for translational research studies; on-line data repository and statistical analyses; minorities, ethnicity and access to care; education. Dr. Goss also leads an active exchange program of international trainees and a growing global telemedicine forum.

Publications

Powered by Harvard Catalyst
  • Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol 2015. PubMed
  • Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE, . Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer 2015; 51:685-96. PubMed
  • Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 2015; 33:265-71. PubMed
  • Goss PE. Extending endocrine therapy in women with hormone receptor-positive breast cancer. Clin Adv Hematol Oncol 2015; 13:20-2. PubMed
  • Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res 2015; 17:56. PubMed
  • Strasser-Weippl K, Ramchandani R, Fan L, Li J, Hurlbert M, Finkelstein D, Shao ZM, Goss PE. Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis. Breast Cancer Res Treat 2015; 149:255-61. PubMed
  • Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in younger and older postmenopausal breast cancer patients. World J Clin Oncol 2014; 5:1088-96. PubMed
  • Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol 2014; 15:e279-e289. PubMed
  • Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Hiltz A, Brundage M, Pater JL, Tu D, Richardson H. Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. J Clin Oncol 2014. PubMed
  • Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail C, St Louis J, Chan A. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol 2014; 15:489-538. PubMed
  • Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol 2014; 15:474-82. PubMed
  • Fan L, Liedke PE, Isakoff SJ, St Louis J, Ryan PD, Goss PE. Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review. Clin Breast Cancer 2014; 14:e41-5. PubMed
  • Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE. Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury. J Clin Oncol 2014. PubMed
  • Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I. Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. Oncologist 2014; 19:348-9. PubMed
  • Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I. Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer. Oncologist 2014; 19:346-7. PubMed
  • Liedke PE, Finkelstein DM, Szymonifka J, Barrios CH, Chavarri-Guerra Y, Bines J, Vasconcelos C, Simon SD, Goss PE. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomarkers Prev 2014; 23:126-33. PubMed
  • Chavarri-Guerra Y, St Louis J, Liedke PE, Symecko H, Villarreal-Garza C, Mohar A, Finkelstein DM, Goss PE. Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective. BMC Cancer 2014; 14:658. PubMed
  • Strasser-Weippl K, Goss PE. Suitable trial designs and cohorts for preventive breast cancer agents. Nat Rev Clin Oncol 2013; 10:677-87. PubMed
  • Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14:1067-76. PubMed
  • Chapman JA, Nielsen TO, Ellis MJ, Bernard P, Chia S, Gelmon KA, Pritchard KI, Maitre AL, Goss PE, Leung S, Shepherd LE, Bramwell VH. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort. Breast Cancer Res 2013; 15:R71. PubMed
  • Strasser-Weippl K, Badovinac-Crnjevic T, Fan L, Goss PE. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. Breast 2013; 22 Suppl 2:S171-5. PubMed
  • Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. Journal of the National Cancer Institute 2013; 105:1036-42. PubMed
  • Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial. J Clin Oncol 2013; 31:1398-404. PubMed
  • Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G. Planning cancer control in Latin America and the Caribbean. Lancet Oncol 2013; 14:391-436. PubMed
  • Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, . Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14:88-96. PubMed
  • Higgins MJ, Liedke PE, Goss PE. Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. Crit Rev Oncol Hematol 2012. PubMed
  • Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. Breast Cancer Res Treat 2012. PubMed
  • Chávarri-Guerra Y, Villarreal-Garza C, Liedke PE, Knaul F, Mohar A, Finkelstein DM, Goss PE. Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol 2012; 13:e335-43. PubMed
  • Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE. Breast cancer in Brazil: present status and future goals. Lancet Oncol 2012; 13:e95-e102. PubMed
  • Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, . Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381-91. PubMed
  • Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, Lingle WL, Goss PE, Li R, Aiyar SE, Scott CG, Pankratz VS, Santen RJ, Ingle JN. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2010; 125:243-52. PubMed
  • Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010; 10:871-7. PubMed
  • Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM. Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. J Clin Oncol 2010; 28:4674-82. PubMed
  • Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 2010; 120:427-35. PubMed
  • Goss PE,Qi S,Hu H. Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats. J Steroid Biochem Mol Biol 2009; 113:233-40. PubMed
  • Goss PE. Extending the benefits of adjuvant therapy in early HR+ breast cancer. Breast Cancer Res Treat 2008; 112 Suppl 1:45-52. PubMed
  • Goss PE,Muss HB,Ingle JN,Whelan TJ,Wu M. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 2008; 8:411-7. PubMed
  • Miller WR,Bartlett J,Brodie AM,Brueggemeier RW,di Salle E,Lonning PE,Llombart A,Maass N,Maudelonde T,Sasano H,Goss PE. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008; 13:829-37. PubMed
  • Pater JL, Goss P, Meyer R. Stopping trials for benefit can (sometimes) benefit patients. J Clin Oncol 2008; 26:2787-8; author reply 2788. PubMed
  • Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clin Cancer Res 2008; 14:2601-8. PubMed
  • Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117:2104-13. PubMed
  • Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 2008; 26:1956-64. PubMed
  • Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26:1948-55. PubMed
  • Pater J, Tu D, Shepherd L, Ingle JN, Goss PE. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 2008; 108:265-9. PubMed
  • Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. Journal of the National Cancer Institute 2008; 100:252-60. PubMed
  • Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer 2007; 112:673-8. PubMed
  • Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2007; 112:700-9. PubMed
  • Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008; 13:16-24. PubMed
  • Chambers AF,Goss PE. Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Res 2008; 10:114. PubMed
  • Goss P, Wu M. Application of aromatase inhibitors in endocrine responsive breast cancers. Breast 2007; 16 Suppl 2:S114-9. PubMed
  • Gligorov J, Pritchard K, Goss P. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. Breast 2007; 16 Suppl 3:S1-9. PubMed
  • Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Ales-Martinez JE. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 2008; 7:895-900. PubMed
  • Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH Jr, Langecker P, Blanchett D. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol 2007; 25:4961-6. PubMed
  • Wu M, Goss PE. Update on the use of letrozole in breast cancer. Expert Opin Pharmacother 2007; 8:2329-45. PubMed
  • Goss P, von Eichel L. Summary of aromatase inhibitor trials: the past and future. J Steroid Biochem Mol Biol 2007; 106:40-8. PubMed
  • Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12:756-65. PubMed
  • Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007; 72:666-71. PubMed
  • Goss PE, Qi S, Hu H, Cheung AM. The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model. Breast Cancer Res Treat 2007; 103:293-302. PubMed
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL,. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007; 25:2006-11. PubMed
  • Booth CM, Pater JL, Goss PE. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen. Cancer 2007; 109:1927-8; author reply 1928. PubMed
  • del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS. Mammographic breast density and race. AJR Am J Roentgenol 2007; 188:1147-50. PubMed
  • Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 2006; 16:204-10. PubMed
  • Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer 2007; 7:489-92. PubMed
  • Goss PE, Strasser-Weippl K, Qi S, Hu H. Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model. BMC Cancer 2007; 7:26. PubMed
  • Goss PE. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat 2007; 105 Suppl 1:45-53. PubMed
  • Delea TE, Karnon J, Goss PE. Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature. Ann Oncol 2007; 18:197-8; author reply 198-9. PubMed
  • Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006; 24:5305-12. PubMed
  • Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 2006; 17:1637-43. PubMed
  • Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11:1047-57. PubMed
  • Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006; 99:295-300. PubMed
  • Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 2006; 12:4790-3. PubMed
  • Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-35. PubMed
  • Ryan PD, Goss PE. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist 2006; 11:718-31. PubMed
  • Cigler T, Goss PE. Aromatase inhibitor withdrawal response in metastatic breast cancer. J Clin Oncol 2006; 24:1955-6. PubMed
  • Goss PE. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol 2006; 33:S8-12. PubMed
  • Pritchard KI, Goss PE, Shepherd L. The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies. Breast 2006; 15 Suppl 1:S14-20. PubMed
  • Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006; 24:237-50. PubMed
  • Ryan PD, Goss PE. The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer. Nat Clin Pract Oncol 2005; 2:596-7. PubMed
  • Suen TC, Tang MS, Goss PE. Model of transcriptional regulation of the BRCA1-NBR2 bi-directional transcriptional unit. Biochim Biophys Acta 2005; 1728:126-34. PubMed
  • Strasser-Weippl K, Goss PE. Advances in adjuvant hormonal therapy for postmenopausal women. J Clin Oncol 2005; 23:1751-9. PubMed
  • Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats. J Steroid Biochem Mol Biol 2004; 92:79-87. PubMed
  • Goss PE, Qi S, Josse RG, Pritzker KP, Mendes M, Hu H, Waldman SD, Grynpas MD. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34:384-92. PubMed
  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-802. PubMed
  • Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause 2010; 17:908-16. PubMed
  • Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS 2008; 116:552-68. PubMed
Hide